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Abstract
Previous structure-activity relationship studies of salvinorin A have shown that modification of the
acetate functionality off the C-2 position to a methoxy methyl or methoxy ethyl ether moiety leads
to increased potency at KOP receptors. However, the reason for this increase remains unclear.
Here we report our efforts towards the synthesis and evaluation of C-2 constrained analogs of
salvinorin A. These analogs were evaluated at opioid receptors in radioligand binding experiments
as well as in the GTP-γ-S functional assay. One compound, 5, was found to have affinity and
potency at κ opioid (KOP) receptors comparable to salvinorin A. In further studies, 5 was found to
attenuate cocaine-induced drug seeking behavior in rats comparably to salvinorin A. This finding
represents the first example of a salvinorin A analog that has demonstrated anti-addictive
capabilities.
Introduction
The neoclerodane diterpene salvinorin A is the active component of Salvia divinorum L.
Epling&Jativa (Lamiaceae), a widely available psychoactive plant.1 S. divinorum is a
member of the sage family and is indigenous to Oaxaca, Mexico.1, 2 For centuries it has
been used by the Mazatec Indians in divination ceremonies as well as to treat headaches,
rheumatism, and panzón de barrego, a semi-magical disease.1 Salvinorin A was isolated
from S. divinorum and determined to be a potent hallucinogen when vaporized and inhaled,
with an active dose in humans of 4.5 – 21 μg/kg.3 This rivals the potency of classical
hallucinogens such as lysergic acid diethylamide (LSD) and 4-bromo-2,5-
dimethoxyamphetamine (DOB).4 However, unlike the classical hallucinogens, salvinorin A
does not have activity at serotonin 5HT2A receptors.4–6 Instead, it was found to be a potent
and selective κ opioid (KOP) receptor agonist.4 KOP agonists have received recent research
focus because they may have applications as drug abuse therapeutics.7
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Recently it has been reported that converting the acetate group at the C-2 position of
salvinorin A to a methoxy- or ethoxymethyl ether produces ligands of greater affinity and
potency at KOP receptors than salvinorin A.8, 9However, the structural basis that underlies
these changes in affinity and potency is unknown. We hypothesize that the ether moieties at
C-2 are relatively flexible and can adopt different conformations when interacting with KOP
receptors; for example, an eclipsed or an extended conformation as shown in Figure 1. Thus,
we applied the concept of conformational constraint in order to design ligands in which the
flexible portions are pre-organized in the hopes that such ligands would aid in the
elucidation of the structural basis for the observed changes in affinity and potency. Here, we
report our synthetic efforts towards this end, as well as the biological evaluation of C-2
constrained analogs of salvinorin A.
Chemistry
Compounds 3 and 4 were synthesized according to Scheme 1. Salvinorin A (1) was
extracted from commercially available dried S. divinorum leaves and converted to salvinorin
B (2) as previously described.10 Treatment of 2 with either chloromethyl methyl ether or
chloromethyl ethyl ether in the presence of N,N-diisopropylethylamine (DIPEA) afforded
the previously reported ethers 3 and 4.8
Compounds 5, 6, and 7 were synthesized according to Scheme 2. A solution of 2 in CH2Cl2
was treated with 3,4-dihydro-2H-pyran or 2,3-dihydrofuran in the presence of a catalytic
amount of pyridinium p-toluene sulfonate (PPTS) to afford the previously reported
tetrahydropyran (5 and 6) and novel tetrahydrofuran (7) C-2 constrained derivatives.8 Under
these conditions, diastereomers were formed and, in the case of tetrahydropyrans 5 and 6,
were separated from each other through flash column chromatography, and characterized by
NMR, and X-ray crystallography (Figures 2 and 3). In the case of the diastereomers of 7,
they were separated from each other through flash column chromatography and
characterized by NMR.
NMR spectroscopy and X-Ray crystallography were used to assign the stereochemistry of
the new stereocenter in compounds 5 and 6. In carbohydrate chemistry, anomeric 1JC,H
values are useful for the assignment of configuration at that position since pyranoses with an
axial proton have a 1JC,H value that is approximately 10 Hz lower than the corresponding
value in compounds with an equatorial anomeric proton.11, 12 Using this method, we
determined that the anomeric 1JC,H values for compounds 5 and 6 are 168.55 Hz and 159.36
Hz, respectively, which are consistent with previous reports of substituted pyranoses. Given
these data, we propose that 5 contains an equatorial, β-H (R) and 6 contains an axial, α-H (S)
(Figure 2).13 Compound 5, the less polar diastereomer, was crystallized and we determined
its structure using X-ray crystallography, confirming the orientation of the hydrogen
predicted by our NMR analysis (Figure 3). In this structure, the tetrahydropyran moiety
forms an α-glycosidic bond with the salvinorin A core in an axial position and the anomeric
hydrogen in an equatorial, β position. Subsequently, compound 6 must be the other
diastereomer.
Compounds 8 and 9 were synthesized according to Scheme 2. In the presence of a catalytic
amount of PPTS, a suspension of 2 in ethyl vinyl ether was refluxed for 2 h, affording a
diastereomeric mixture of previously reported ethers 8.8 These diastereomers were separated
from each other by flash column chromatography, and the less polar diastereomer (8a) was
isolated. The more polar diastereomer (8b) appeared to degrade during purification and
could not be completely purified (purity = 81.938 %) through trituration, flash column
chromatography, or HPLC. The impurity was not determined, although there was no amount
of 8a present as detectable by HPLC. Both 8a and 8b were characterized by NMR. In order
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to produce novel ether 9, ethyl vinyl ether was added to a solution of Br2 in CH2Cl2,
followed by the addition of DIPEA and finally 2. These conditions afforded a mixture of
diastereomers which were subsequently separated from each other by HPLC and
characterized by NMR.
Compounds 10, 11, and 12 were synthesized according to Scheme 2. Following a literature
procedure, a mixture of acetic ahydride and acetic acid was added to a mixture of 2 in
pyridine at 0 °C.14 The mixture was allowed to warm to room temperature and stirred for 30
min, affording formate 10. Known carbonate 119, 15 was produced by treating a solution of 2
in CH2Cl2 with ethyl chloroformate in the presence of DMAP and TEA at room temperature
for 24 h. Following a literature procedure, carbamate 12 was produced by treating a mixture
of 2 in pyridine with ethyl isocyanate at 35 °C overnight.16
Finally, compound 14 was synthesized according to Scheme 3. This compound was inspired
by a previously published analog (15) that incorporated the piperidylamide in place of the
furan ring of 1, and demonstrated retained affinity for the KOP receptor.17 Through the
synthesis and evaluation of compound 14, we sought to combine both the piperidyl amide
and methoxy methyl ether features into one molecule that would have high KOP receptor
affinity compared to 1. Following a procedure developed in our laboratory, the furan ring of
3 was oxidatively degraded to carboxylic acid 13 using catalytic RuCl3·3H2O in the
presence of NaIO4.18 With 13 in hand, standard peptide coupling conditions (as employed
before in our laboratory) were used to generate amide 14.17
Biology
Compounds 3–12, and 14 were evaluated for affinity at human opioid receptors using
methodology previously described (Table 1).19, 20 For previously reported ethers 3 and 4,
the results of the radioligand binding assay are in agreement with published data.8 In past
literature reports, the tetrahydropyran diastereomers 5 and 6 were not completely separated
from each other before biological evaluation. For a mixture of predominantly one of the
diastereomers, absolute configuration unknown, the reported binding affinity and potency
were Ki = 4.0 ± 0.4 nM and EC50 = 2.8 ± 0.3 nM.8 We were able to separate and isolate
each diastereomer, and the observed binding affinities for 5 and 6 in our hands reveal a
eutomer (5) and a distomer (6), indicating a preference for the hydrogen of the new
stereocenter to be in the β position or R configuration. Interestingly, the related
tetrahydrofuran derivatives 7a and 7b have modest binding affinities at KOP receptors that
are very similar to each other and show no preference for stereochemistry. One possible
explanation is that by reducing the ring size by one carbon, the orientation of the new
stereocenter of 7a and 7b in the receptor has been altered (relative to 5 and 6) such that
neither diastereomer has a particularly unfavorable interaction with the receptor.
In similar fashion to the tetrahydropyran derivatives, ethers 8a and 8b are previously
reported, but the diastereomers were not completely separated from each other before
biological evaluation.8 The published data show both diastereomers as having very similar
binding affinities (Ki = 11 ± 1 nM and Ki =6.6 ± 0.3 nM) and potencies (10 ± 1 nM and 5.7
±0.7 nM). We were able to separate the diastereomers and isolate the less polar one (8a). By
HPLC, the more polar diastereomer (8b) appeared to degrade during purification and was
not completely purified (purity = 81.938 %), although it is important to note that there was
no amount of 8a present. In our hands ethers 8a and 8b also reveal a eutomer (8a) and
distomer (8b), indicating a preference for the configuration of the new stereocenter, and
reflecting our observations of tetrahydropyrans 5 and 6. In our NMR characterization of 8a
and 8b, we observed 1JC,H values at the new stereocenter that followed the accepted trend of
pyranoses as previously described, although the difference was less pronounced (data not
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shown). Given this observation and the pattern in the radioligand binding data in which the
less polar diastereomers 5 and 8a had the highest affinity, we propose that the configuration
of the new stereocenter in 8a is very likely the same as that of 5. However, this needs to be
confirmed through X-ray crystallography. The related brominated ethers 9a and 9b had poor
binding affinities at the KOP receptor and show no preference for stereochemistry. One
explanation for this observation is that the bromine atom was too bulky and/or too lipophilic
such that it precluded receptor binding altogether.
Formate 10 produced radioligand binding affinity data that was well in agreement with
published reports.14, 22 However, in our hands compounds 11 and 12 behaved differently
than previously reported. In two previously published radioligand binding studies, carbonate
11 showed no appreciable affinity at the KOP receptor vs. [3H]bremazocine15 or
[3H]diprenorphine.9 Our data show that carbonate 11 displaces [3H]U69,593 at the KOP
receptor at Ki = 171 ± 7 nM. Additionally, carbamate 12 was reported to have a KOP
receptor binding affinity (vs. [3H]diprenorphine) and potency of Ki = 462 ± 20 nM and EC50
= >1000 nM.16 We found that while carbamate 12 has no appreciable affinity at the other
opioid receptors, it does displace [3H]DAMGO at the μ opioid(MOP) receptor at Ki = 1540
± 140 nM. While this particular Ki is unimpressive, it does agree with previously published
reports in which alkyl carbamates at the C-2 position of salvinorin A were found to lose
KOP affinity and gain MOP affinity relative to the parent compound.
Compound 14 is reflective of a furan ring analog of 1 that was previously produced in our
lab (Scheme 3). Amide 15 had binding affinity at KOP receptors of Ki = 140 ± 10 nM, and
potency and efficacy of ED50 = 5110 ± 1800 nM, Emax = 85 ± 13.17 Our hypothesis was that
through the combination of the amide in place of the furan ring (from 15), and the methoxy
methyl ether in place of the C-2 acetate (from 3), we would be able to observe improved (or
at least retained) binding affinity relative to the parent analogs. Through the addition of the
methoxy methyl ether off the C-2 position, the KOP receptor binding affinity of 14 was
improved over that of 15 by approximately 2-fold to Ki = 59 ± 4 nM. However, the binding
affinity of 14 is roughly 31-fold worse compared to 3. Still, the improvement in receptor
binding affinity from compound 14 over compound 15 is of similar magnitude (roughly 2–4
fold) to the improvement in receptor binding affinity from compound 3 over compound 1.
Compounds 3, 4, 5, 7, 8a, and 14 were also evaluated for functional activity at KOP
receptors using a [35S]GTP-γ-S functional assay (Table 2).19, 20 Compounds 3, 4, 5, and 8a
were found to have potencies comparable to or better than 1 as agonists. Compounds 7a and
7b were observed to be approximately 30-and 17-fold less potent than 1 as agonists,
respectively. Finally, compound 14 was 48-fold less potent as an agonist than 1, which is
actually an approximately 2.5-fold improvement over the previously published furan analog
15 (approximately 125-fold less potent than 1 as an agonist).17 However, 14 was also
roughly 322-fold less potent than 3 as an agonist. Thus, the incorporation of the methoxy
methyl ether at C-2 improved the binding affinity and potency of compound 14 over parent
compound 15 by approximately 2-fold and 2.5 fold, respectively. These improvements are
of similar magnitude to the improvements in the binding affinity and potency
(approximately 4-fold and 7-fold, respectively) of compound 3 over compound 1. However,
the combination of furan substitution with C-2 acetate substitution in compound 14
ultimately greatly decreased the potency of the compound relative to ether 3 as well as
compound 1.
Finally, among the compounds reported, compound 5 had KOP receptor binding affinity and
potency comparable to 1. Compound 5 also lacks a hydrolyzable ester at C-2 and other
analogs of 1 with this particular feature have been found to have a greater duration of action
than 1.23 Therefore, compound 5 met our criteria for evaluation in vivo. Using methodology
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previously reported, compound 5 was evaluated for its effect on cocaine-induced drug-
seeking in rats at doses of 0.3 mg/kg and 1 mg/kg (Figure 4).24
Briefly, rats were trained on a fixed ratio 5 schedule of reinforcement for cocaine self-
administration where a single cocaine infusion was received (0.5 mg/kg/infusion, paired
with a light cue) for every 5 correct active lever responses. The first phase involved daily 2 h
sessions until responding showed <20% variation across three consecutive days (cocaine
baseline). In phase 2, cocaine was replaced with heparinised saline and daily 2 h sessions
continued in the same operant chambers until active lever responses were <20 for a session
(typically 2–3 days). When the extinction criteria had been achieved, reinstatement of
cocaine-induced cocaine-seeking was tested the following day. Animals received IP
injections of vehicle (75% DMSO), compound 5 (0.3 mg/kg or 1 mg/mg), or compound 1
(0.3 mg/kg) 5–10 min prior to a priming injection of cocaine (IP, 20 mg/kg). Immediately
following the cocaine injection, animals were placed into the operant chamber and
responding was recorded for a further 2 h. Results show a statistically significant reduction
in responding between vehicle and the 1 mg/kg dose of 5. In fact, this dose appeared to
attenuate responding comparably to 0.3 mg/kg salvinorin A (1), our positive control, which
we have previously shown to attenuate cocaine-primed reinstatement of drug seeking at a
dose of 0.3 mg/kg or greater.24
Conclusions
In summary, we have evaluated C-2 modified analogs of 1 for opioid receptor affinity and
efficacy. We have isolated and confirmed the binding affinities and potencies of two
agonists, compounds 5 and 8a. In comparison to their diastereomers (6 and 8b), these
analogs show preferential interactions with the KOP receptor. Since our NMR-based
assignment of the absolute configuration of compound 5 was confirmed through X-ray
crystallography, and given our observation that the less polar diastereomers appear to have
the highest binding affinities, we propose that the new stereocenter in ether 8a shares the
same absolute configuration as that of tetrahydropyran 5. This will need to be further
investigated through X-ray crystallography. Interestingly, we did not observe a
stereochemical influence in the other related diastereomeric compounds (7a, 7b, 9a, and
9b). This may be accounted for in steric considerations: the smaller ring size of 7a and 7b
has changed their orientation in the receptor such that neither diastereomer interacts
particularly unfavourably; and 9a and 9b are too large and/or lipophilic to allow for receptor
interaction at all. Additionally, we have shown that contrary to previous reports, compound
11 does show affinity for the KOP receptor in radioligand binding assays. We have also
demonstrated that compound 12, in agreement with previous reports, has very little affinity
at KOP receptors, but does have some affinity for the MOP receptor, in agreement with past
radioligand binding studies of similar compounds. We also found that compound 14, which
is reflective of a previously published furan ring analog (15), demonstrated improved
binding affinity over the parent compound upon the incorporation of the methoxy methyl
ether moiety off C-2. However, the potency of 14 relative to compounds 3 and 1 was greatly
diminished. Finally through further evaluation, it was found that compound 5 attenuated
cocaine-induced drug seeking behavior comparably to salvinorin A (1). This finding is
consistent with other reported KOP receptor agonists, and represents the first example of a
salvinorin A analog that has demonstrated anti-addictive capabilities. The identification of
differences in chirality and receptor tolerances for these ring constrained analogs should be
of great value for the design of new compounds and or pharmacophore models of the
binding site of 1.
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Eclipsed (upper) or extended (lower) conformations of the ethoxymethyl ether at C-2
compared to salvinorin A.
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1D 13C NMR spectrum with composite pulse 1H-decoupling (blue) and gated decoupling to
show JC,H (black) for the anomeric carbon of 5(A) and 6 (B).
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X-ray crystallographic structure of 5.
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The effect of 5 on cocaine-induced drug-seeking. In the first phase (cocaine baseline), the
active lever delivered an infusion of cocaine. Recorded active lever responses consisted of
access to cocaine (0.5 mg/kg/inf) for a period of 2 h in operant chambers. At the beginning
of the second phase (extinction), cocaine was replaced with sterile heparinized saline and
responses were recorded for 2 h, until active lever responses were <20 for a 2 h daily
session. At the beginning of the third phase, animals received an I.P. injection of vehicle
(75% DMSO, N = 7), 5 (0.3 mg/kg, N = 3), 5 (1 mg/kg, N = 6), or 1 (0.3 mg/kg, N = 7) 5–
10 min prior to a priming injection of cocaine (20 mg/kg). Responding in phase 3 was
measured for 2 h (± SEM).
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Reagents and conditions: (a) Na2CO3, MeOH; (b) appropriate chloromethyl ether, DIPEA,
CH2Cl2.
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Reagents and conditions: (a) 3,4-dihydro-2H-pyran or 2,3-dihydrofuran, PPTS, CH2Cl2; (b)
PPTS, ethyl vinyl ether, reflux; (c) Br2, ethyl vinyl ether, DIPEA, CH2Cl2; (d) Ac2O/
HCO2H, pyridine; (e) ethyl chloroformate, DMAP, TEA, CH2Cl2; (f) ethyl isocyanate,
DMAP, pyridine.
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(a) RuCl3·3H2O, NaIO4, CCl4/CH3CN/H2O; (b) piperidine, EDCI, HOBt, TEA, CH2Cl2.
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Table 1
Opioid receptor binding affinity for compounds 3–12, and 14.
Cmpd
Ki ± SD nMa
[3H]DAMGO (μ) [3H]DADLE (δ) [3H]U69,593 (κ)
1b
EC50 = 2860 ± 980
Emax = 75 ± 8 %
>10,000 7.4 ± 0.7
3 390 ± 20 2,840 ± 180 1.9 ± 0.2
4 41 ± 3 1,017 ± 99 3.13 ± 0.40
5 >10,000 >10,000 6.21 ± 0.40
6 >10,000 >10,000 300 ± 23
7a >10,000 >10,000 75 ± 3
7b >10,000 >10,000 81 ± 6
8a 777 ± 40 >5,000 6.7 ± 0.32
8b >5,800 >5,000 1,233 ± 33
9a >3,000 >5,000 5,261 ± 680
9b 3,523 ± 389 >5,000 7,438 ± 764
10c ND ND 41 ± 1
11c ND ND 171 ± 7
12c 1,540 ± 140 ND ND
14 >3,000 >3,000 59 ± 4
a
Receptor binding was performed in CHO cells which express the human MOP, DOP, or KOP receptors. All results are N = 3.
b
Data from reference 21.
c
ND indicates that Ki was found to be >10,000 nM in a range finding study.
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Table 2
[35S]GTP-γ-S functional assay for compounds 3, 4, 5, 7,8a, and 14.
Cmpd ED50 ± SDa (κ) nM Emax ± SDb (κ)
1c 40 ±10 120 ± 2
3 6 ± 1 118 ± 2
4 0.65 ± 0.17 127 ± 5
5 60 ± 6 109 ± 3
7a 1220 ± 230 112 ± 8
7b 690 ± 80 103 ± 4
8a 150 ± 14 101 ± 3
14 1934 ± 239 113 ± 5
a
ED50 = Effective dose for 50% maximal response.
b
Emax is % at which compound stimulates [35S]GTP-γ-Sbinding compared to (−)-U50,488 (500 nM) at KOP receptors.
c
Data from reference 21.
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